Chloroquine Combined with Imatinib Overcomes Imatinib Resistance in Gastrointestinal Stromal Tumors by Inhibiting Autophagy via the MAPK/ERK Pathway

References

• Soreide K, Sandvik OM, Soreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.26618334
   PubMed Web of Science ®Google Scholar
• Landi B, Blay JY, Bonvalot S, et al. Gastrointestinal stromal tumours (GISTs): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis. 2019;51:1223–1231. doi:10.1016/j.dld.2019.07.00631387778
   PubMedGoogle Scholar
• Reichardt P. The story of imatinib in GIST - a Journey through the development of a targeted therapy. Oncol Res Treat. 2018;41(7–8):472–477. doi:10.1159/00048751129895025
   PubMed Web of Science ®Google Scholar
• Mazzocca A, Napolitano A, Silletta M, et al. New frontiers in the medical management of gastrointestinal stromal tumours. Ther Adv Med Oncol. 2019;11:1758835919841946. doi:10.1177/175883591984194631205499
   PubMed Web of Science ®Google Scholar
• von Mehren M, Joensuu H. Gastrointestinal stromal tumors. J Clin Oncol. 2018;36(2):136–143. doi:10.1200/JCO.2017.74.970529220298
   PubMed Web of Science ®Google Scholar
• Li GZ, Raut CP. Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategies. Onco Targets Ther. 2019;12:5123–5133. doi:10.2147/OTT.S18076331308690
   PubMed Web of Science ®Google Scholar
• Villanueva MT. Ripretinib turns off the switch in GIST. Nat Rev Drug Discov. 2019;18(7):499. doi:10.1038/d41573-019-00099-431267077
   PubMed Web of Science ®Google Scholar
• Smith BD, Kaufman MD, Lu W-P, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell. 2019;35(5):738–751 e739. doi:10.1016/j.ccell.2019.04.00631085175
   PubMed Web of Science ®Google Scholar
• Ravegnini G, Sammarini G, Nannini M, et al. Gastrointestinal stromal tumors (GIST): facing cell death between autophagy and apoptosis. Autophagy. 2017;13(3):452–463. doi:10.1080/15548627.2016.125652228055310
   PubMed Web of Science ®Google Scholar
• Miselli F, Negri T, Gronchi A, et al. Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors? Transl Oncol. 2008;1(4):177–186. doi:10.1593/tlo.0815719043528
   PubMed Web of Science ®Google Scholar
• Liu W, Zeng X, Yin Y, et al. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors. Gastric Cancer. 2020;23(1):39–51.31197522
   PubMed Web of Science ®Google Scholar
• Helgason GV, Karvela M, Holyoake TL. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood. 2011;118(8):2035. doi:10.1182/blood-2011-01-33062121693757
   PubMed Web of Science ®Google Scholar
• Ciarcia R, Damiano S, Montagnaro S, et al. Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells. Cell Cycle. 2013;12(17):2839–2848. doi:10.4161/cc.2592023966159
   PubMed Web of Science ®Google Scholar
• Rubin BP, Debnath J. Therapeutic implications of autophagy-mediated cell survival in gastrointestinal stromal tumor after treatment with imatinib mesylate. Autophagy. 2010;6(8):1190–1191. doi:10.4161/auto.6.8.1343020930540
   PubMed Web of Science ®Google Scholar
• Gupta A, Roy S, Lazar AJ, et al. Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci U S A. 2010;107(32):14333–14338. doi:10.1073/pnas.100024810720660757
   PubMed Web of Science ®Google Scholar
• Wicki A, Mandala M, Massi D, et al. Acquired resistance to clinical cancer therapy: a twist in physiological signaling. Physiol Rev. 2016;96(3):805–829. doi:10.1152/physrev.00024.201527142452
   PubMed Web of Science ®Google Scholar
• Sui X, Kong N, Ye L, et al. p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett. 2014;344(2):174–179. doi:10.1016/j.canlet.2013.11.01924333738
   PubMed Web of Science ®Google Scholar
• Zheng S, Huang K-E, Pan Y-L, et al. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance. Gastric Cancer. 2015;18(4):796–802. doi:10.1007/s10120-014-0414-725182956
   PubMed Web of Science ®Google Scholar
• Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528–542. doi:10.1038/nrc.2017.5328751651
   PubMed Web of Science ®Google Scholar
• Vera-Ramirez L, Vodnala SK, Nini R, et al. Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. Nat Commun. 2018;9(1):1944. doi:10.1038/s41467-018-04070-629789598
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sha R, Zhang L, et al. Harnessing copper-palladium alloy tetrapod nanoparticle-induced pro-survival autophagy for optimized photothermal therapy of drug-resistant cancer. Nat Commun. 2018;9(1):4236. doi:10.1038/s41467-018-06529-y30315154
   PubMedGoogle Scholar
• Bryant KL, Stalnecker CA, Zeitouni D, et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2019;25(4):628–640. doi:10.1038/s41591-019-0368-830833752
   PubMed Web of Science ®Google Scholar
• Rosenfeldt MT, O’Prey J, Morton JP, et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature. 2013;504(7479):296–300. doi:10.1038/nature1286524305049
   PubMed Web of Science ®Google Scholar
• Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865–878. doi:10.1038/nrc314322089421
   PubMed Web of Science ®Google Scholar
• Gaestel M. MAPK-Activated Protein Kinases (MKs): novel insights and challenges. Front Cell Dev Biol. 2015;3:88.26779481
   PubMed Web of Science ®Google Scholar
• Sun Y, Liu WZ, Liu T, et al. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res. 2015;35:600–604. doi:10.3109/10799893.2015.103041226096166
   PubMed Web of Science ®Google Scholar
• Liu F, Yang X, Geng M, et al. Targeting ERK, an Achilles’ Heel of the MAPK pathway, in cancer therapy. Acta Pharm Sin B. 2018;8:552–562. doi:10.1016/j.apsb.2018.01.00830109180
   PubMed Web of Science ®Google Scholar
• Lu H, Liu S, Zhang G, et al. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2017;550(7674):133–136. doi:10.1038/nature2404028953887
   PubMed Web of Science ®Google Scholar